Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Drug

AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data

Fineline Cube May 6, 2026
Company Deals

WuXi AppTec to Divest WuXi Advanced Therapies and Oxford Genetics to Altaris LLC

Fineline Cube Dec 25, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...

Company Deals

Basecare Medical and SolarCare Form Alliance to Advance AI in IVF Services

Fineline Cube Dec 25, 2024

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a leading China-based in vitro fertilization (IVF) specialist,...

Company Drug

Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE

Fineline Cube Dec 25, 2024

China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...

Company Drug

CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment

Fineline Cube Dec 24, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Drug

Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China

Fineline Cube Dec 24, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...

Company Drug

Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases

Fineline Cube Dec 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial

Fineline Cube Dec 24, 2024

China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...

Company Drug

AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC

Fineline Cube Dec 24, 2024

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...

Company Deals

Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’

Fineline Cube Dec 24, 2024

US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...

Company Deals

Sanofi and SK bioscience Broaden Partnership to Develop Next-Gen Pneumococcal Vaccines

Fineline Cube Dec 24, 2024

French pharmaceutical major Sanofi (NASDAQ: SNY) and South Korea-based SK bioscience (KRX: 302440) have announced...

Company Deals

Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage

Fineline Cube Dec 24, 2024

China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...

Company Drug

ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors

Fineline Cube Dec 24, 2024

China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC

Fineline Cube Dec 24, 2024

Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...

Company Drug

Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment

Fineline Cube Dec 24, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from...

Company

BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”

Fineline Cube Dec 24, 2024

China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...

Company Deals

RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904

Fineline Cube Dec 24, 2024

US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...

Company Deals

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development

Fineline Cube Dec 24, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic...

Company Drug

GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial

Fineline Cube Dec 23, 2024

UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44...

Company Drug

Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment

Fineline Cube Dec 23, 2024

US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...

Company Drug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

Fineline Cube Dec 23, 2024

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...

Posts pagination

1 … 234 235 236 … 660

Recent updates

  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
  • China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026
  • UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Company

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.